New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening

BD Onclarity™ HPV Assay and New Guidelines - The BD Onclarity™ HPV Assay has been officially added to the ASCCP Enduring Risk-Based Management Guidelines due to its ability to individually identify more high-risk types of HPV [1][2] - The new guidelines represent a significant advancement in cervical cancer prevention and management, offering a more precise and effective approach to HPV screening, which improves treatment design and supports efforts to eliminate cervical cancer [2] - The BD Onclarity™ HPV Assay employs extended genotyping, allowing for a more detailed analysis of HPV types present in a person's body, which is crucial as HPV is the cause of virtually all cervical cancer [3] Extended Genotyping and Clinical Benefits - Traditional HPV tests typically identify no more than two high-risk HPV types individually, while the BD Onclarity™ HPV Assay can identify six of the 14 cancer-causing HPV types individually and group the remaining seven into three pooled results [4] - This extended genotyping allows for more precise risk assessment, persistence-tracking, and personalized treatment plans, aligning with new clinical recommendations [4] - Clinicians can more effectively manage high-risk cases and guide follow-up for low-risk patients by identifying specific HPV types and tracking them individually across patient visits [5] Self-Collection and Accessibility - The new ASCCP guidelines support the use of self-collection methods for cervical cancer screening, which is also offered with the BD Onclarity™ HPV Assay in healthcare settings [5] - Self-collection methods make it easier for women and people with a cervix to get screened, especially those facing barriers to traditional screening methods such as lack of time or discomfort with pelvic exams [5] - The recent FDA approval for self-collection in healthcare settings and the inclusion of extended genotyping in the ASCCP guidelines are expected to significantly improve access to potentially life-saving screening and the precision of screening results [6] Integration of New Technologies - The new guidelines integrate new technologies and approaches to improve cancer prevention for high-risk individuals and decrease unnecessary procedures in lower-risk individuals [7] - Extended genotyping results provide additional risk stratification beyond a pooled high-risk result, and repeated detection of the same HPV type, even a lower-risk strain, is associated with a much higher risk of cervical pre-cancer compared to single-time point detection [7] ASCCP Mobile Application Update - The ASCCP guidelines will soon be used to update the popular ASCCP mobile application, which is downloaded by over 150,000 clinicians in the US to help inform their decision-making and improve patient care [8] USPSTF Recommendations - Self-collection for HPV/cervical cancer screening is among the recommendations recently released for public comment by the US Preventive Services Task Force (USPSTF), which guides healthcare providers in the US on the effectiveness of specific preventive care services [9] About BD - BD is one of the largest global medical technology companies, advancing health by improving medical discovery, diagnostics, and the delivery of care [10] - The company develops innovative technology, services, and solutions to advance clinical therapy for patients and clinical processes for healthcare providers, with a presence in virtually every country and partnerships to address global health challenges [11]